$84.78
0.70% today
Nasdaq, Oct 09, 05:45 pm CET
ISIN
US45337C1027
Symbol
INCY

Incyte Stock price

$85.38
-1.18 1.36% 1M
+28.41 49.87% 6M
+16.31 23.61% YTD
+19.64 29.88% 1Y
+17.80 26.34% 3Y
-7.40 7.98% 5Y
-18.06 17.46% 10Y
+81.01 1,853.78% 20Y
Nasdaq, Closing price Wed, Oct 08 2025
-1.79 2.05%
ISIN
US45337C1027
Symbol
INCY
Industry

Key metrics

Basic
Market capitalization
$16.7b
Enterprise Value
$14.3b
Net debt
positive
Cash
$2.4b
Shares outstanding
194.1m
Valuation (TTM | estimate)
P/E
19.5 | 13.5
P/S
3.6 | 3.4
EV/Sales
3.1 | 2.9
EV/FCF
14.9
P/B
4.0
Financial Health
Equity Ratio
63.3%
Return on Equity
1.0%
ROCE
21.9%
ROIC
63.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.6b | $4.9b
EBITDA
$1.0b | $1.7b
EBIT
$994.5m | $1.5b
Net Income
$870.9m | $1.2b
Free Cash Flow
$958.1m
Growth (TTM | estimate)
Revenue
18.9% | 16.4%
EBITDA
1,057.5% | 1,164.4%
EBIT
1,425.1% | 1,260.6%
Net Income
794.8% | 3,654.8%
Free Cash Flow
793.6%
Margin (TTM | estimate)
Gross
93.4%
EBITDA
22.2% | 34.7%
EBIT
21.7%
Net
19.0% | 24.8%
Free Cash Flow
20.9%
More
EPS
$4.4
FCF per Share
$4.9
Short interest
6.3%
Employees
3k
Rev per Employee
$1.6m
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,997 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Incyte forecast:

16x Buy
48%
16x Hold
48%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a Incyte forecast:

Buy
48%
Hold
48%
Sell
3%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,585 4,585
19% 19%
100%
- Direct Costs 302 302
24% 24%
7%
4,283 4,283
19% 19%
93%
- Selling and Administrative Expenses 1,293 1,293
13% 13%
28%
- Research and Development Expense 1,971 1,971
17% 17%
43%
1,019 1,019
1,058% 1,058%
22%
- Depreciation and Amortization 24 24
6% 6%
1%
EBIT (Operating Income) EBIT 995 995
1,425% 1,425%
22%
Net Profit 871 871
795% 795%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
Business Wire
one day ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 28, 2025. The schedule for the press release and conference call/webcast is as follows: Q3 2025 Press Release: October 28, 2025 at 7:00 a.m. ET Q3 2025 Conference Call: October 28, 2025 at 8:00 a.m. ET ...
Positive
Seeking Alpha
3 days ago
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...
Neutral
GlobeNewsWire
11 days ago
SHENZHEN, CHINA, Sept. 28, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by C...
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,617
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today